The eight main blood types are A+, A-, B+, B-, O+, O-, AB+, and AB-. The most common blood type in the United States is O-positive, with around 38 percent of the population having this type of blood. However, blood type O-positive is more common in Latino-Americans than other ethnicities, with around 53 percent of Latino-Americans with this blood type, compared to 47 percent of African Americans and 37 percent of Caucasians. Blood donation The American Red Cross estimates that every two seconds someone in the United States needs blood or platelets, highlighting the importance of blood donation. It was estimated that in 2021, around 6.5 million people in the U.S. donated blood, with around 1.7 million of these people donating for the first time. Those with blood type O-negative are universal blood donors, meaning their blood can be transfused for any blood type. Therefore, this blood type is the most requested by hospitals. However, only about seven percent of the U.S. population has this blood type. Blood transfusion Blood transfusion is a routine procedure that involves adding donated blood to a patient’s body. There are many reasons why a patient may need a blood transfusion, including surgery, cancer treatment, severe injury, or chronic illness. In 2021, there were around 10.76 million blood transfusions in the United States. Most blood transfusions in the United States occur in an inpatient medicine setting, while critical care accounts for the second highest number of transfusions.
The most common blood type among the population in the United States is O-positive. Around 53 percent of the Latino-American population in the U.S. has blood type O-positive, while only around 37 percent of the Caucasian population has this blood type. The second most common blood type in the United States is A-positive. Around 33 percent of the Caucasian population in the United States has A-positive blood type. Blood type O-negative Those with blood type O-negative are universal donors as this type of blood can be used in transfusions for any blood type. O-negative blood type is most common in the U.S. among Caucasian adults. Around eight percent of the Caucasian population has type O-negative blood, while only around one percent of the Asian population has this blood type. Only around seven percent of all adults in the United States have O-negative blood type. Blood Donations The American Red Cross estimates that someone in the United States needs blood every two seconds. However, only around three percent of age-eligible people donate blood yearly. The percentage of adults who donated blood in the United States has not fluctuated much for the past two decades. In 2021, around 15 percent of U.S. adults donated blood, the same share reported in the year 2003.
This statistic illustrates the distribution of blood groups in the French population, according to the Rhesus system. It shows that less than *** percent of French people had the blood group AB negative.
Complete blood count of the household population, by sex and age group.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Data used to determine the quantities plotted in Figs 2 and 3: ln(di/fi) and , with di being the fractions of infected having blood group i, fi is the fraction of population with blood group i and represent the susceptibility of the population to become infected.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
IntroductionABO blood type A was reported to correlate with an increased risk of acute respiratory distress syndrome (ARDS) in white patients with severe sepsis and major trauma compared with patients with other blood types. Information regarding ABO phenotypes and major outcomes in patients with ARDS is unavailable. The primary aim was to determine the relationship between ABO blood type A and intensive care unit (ICU) mortality in patients with acute hypoxemic respiratory failure (AHRF). The secondary aim was to describe the association between ABO blood type A and ICU length of stay (LOS) in this study population.MethodsIn a multicenter, retrospective cohort study, we collected the clinical records of patients admitted from January 2012 to December 2014 in five ICUs of Northern Italy. We included adult white patients admitted to the ICU who were diagnosed with AHRF requiring mechanical ventilation.ResultsThe electronic records of 1732 patients with AHRF were reviewed. The proportion of patients with ABO blood type A versus other blood types was 39.9% versus 60.1%. ICU mortality (25%) and ICU LOS (median [interquartile range], 5 [2–12] days) were not different when stratified by ABO blood type (ICU mortality, overall p value = 0.905; ICU LOS, overall p value = 0.609). SAPSII was a positive predictor of ICU mortality (odds ration [OR], 32.80; 95% confidence interval [CI], 18.80–57.24; p < 0.001) and ICU LOS (β coefficient, 0.55; 95% CI, 0.35–0.75; p < 0.001) at multivariate analyses, whereas ABO blood type did not predict ICU outcome when forced into the model.ConclusionABO blood type did not correlate with ICU mortality and ICU LOS in adult patients with AHRF who were mechanically ventilated.
This statistic illustrates the distribution of blood groups in the French population, according to the ABO system. It states that less than 5 percent of French people have the AB blood group.
https://dataintelo.com/privacy-and-policyhttps://dataintelo.com/privacy-and-policy
The global ABO blood type test kit market size was valued at USD 780 million in 2023 and is projected to reach USD 1.2 billion by 2032, growing at a CAGR of 4.8% during the forecast period. The market for ABO blood type test kits is experiencing robust growth primarily driven by increasing demand for blood transfusion services, advancements in diagnostic technologies, and the rising prevalence of chronic diseases necessitating blood type testing. These factors contribute significantly to the market's expansion and its optimistic outlook.
One of the primary growth factors for the ABO blood type test kit market is the increasing number of surgical procedures and trauma cases worldwide, which demand immediate and accurate blood typing. Additionally, the growing awareness about the importance of blood typing in organ transplantation and prenatal testing further propels the market. The surge in blood donation drives and the need for efficient blood bank management systems, which rely heavily on accurate blood type testing, also significantly contribute to market growth.
Technological advancements in diagnostic techniques, such as the development of rapid test kits that offer quick and reliable results, are another critical driver of market expansion. These innovations have made blood typing more accessible and convenient, particularly in remote and underserved areas. The rising adoption of point-of-care testing, which allows for blood type determination outside traditional laboratory settings, is also enhancing the market's growth prospects.
The increasing prevalence of chronic diseases, such as cancer and kidney disorders, which often require regular blood transfusions, is a significant factor fueling the demand for ABO blood type test kits. Moreover, the aging global population, which is more susceptible to various medical conditions requiring blood transfusions, contributes to the sustained demand for these kits. Public health initiatives and government policies promoting regular health check-ups and blood donation are also playing a crucial role in driving the market forward.
From a regional perspective, North America holds a dominant position in the ABO blood type test kit market due to its well-established healthcare infrastructure, high awareness levels, and significant investments in healthcare technologies. Europe follows closely, driven by similar factors along with a strong focus on research and development. The Asia Pacific region is expected to witness the fastest growth, attributed to its large population base, increasing healthcare expenditures, and rising awareness about blood-related health issues. Other regions, including Latin America and the Middle East & Africa, are also showing promising growth potential due to improving healthcare facilities and increasing government initiatives.
The ABO blood type test kit market is segmented by product type into rapid test kits and laboratory test kits. Rapid test kits are designed for quick and efficient blood typing, providing results in a matter of minutes. These kits are particularly useful in emergency situations, field settings, and for point-of-care testing. The demand for rapid test kits is driven by their ease of use, minimal training requirements, and the ability to deliver immediate results, making them highly suitable for use in various non-laboratory settings.
Laboratory test kits, on the other hand, are designed for use in clinical laboratories and provide highly accurate and reliable results. These kits are typically used in hospitals, diagnostic laboratories, and blood banks where precision is crucial. The demand for laboratory test kits is driven by the increasing number of diagnostic procedures and the need for accurate blood type determination in critical medical situations. These kits often employ advanced technologies such as gel cards and microplates, contributing to their high accuracy and reliability.
The rapid test kits segment is expected to witness significant growth during the forecast period due to the increasing adoption of point-of-care testing and the rising need for quick and efficient blood type determination in emergency and remote settings. The convenience and speed offered by rapid test kits are making them increasingly popular among healthcare providers and individual consumers alike. Additionally, advancements in rapid testing technologies are further enhancing the accuracy and reliability of these kits, contributing to their growing demand.
<brThis statistic displays the share of organ donors in the United Kingdom (UK) in 2023/24, by blood group. The largest group of organ donors at 49 percent had blood group O, followed by 36 percent with blood group A.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
BackgroundABO blood group has been associated with cardiovascular disease and cancer. However, whether ABO blood group is associated with nonalcoholic fatty liver disease (NAFLD) remains unknown. The present study aimed to clarify this issue.MethodsA hospital-based case-control study was performed in southwestern China. A total of 583 newly ultrasound-diagnosed NAFLD cases and 2068 controls were included. The adjusted odds ratios (ORs) and 95% confidence intervals (CIs) of developing NAFLD were calculated by multivariate logistic regression. A propensity score was developed for adjustment and matching.ResultsThe proportions of blood groups A, B, AB and O were 31%, 26%, 8% and 35%, respectively. Non-O blood groups were found to be significantly associated with an increased risk of NAFLD (the fully adjusted OR = 1.51, 95% CI: 1.19, 1.91); moreover, compared with blood group O, the fully adjusted ORs of developing NAFLD were 1.50 (95% CI: 1.13, 1.99) for blood group A, 1.59 (95% CI: 1.19, 2.14) for blood group B, and 1.37 (95% CI: 0.86, 2.18) for blood group AB. Similar results were obtained in both propensity-score-adjusted and propensity-score-matched analyses. No evidence of significant effect modification for the association of ABO blood group with the risk of NAFLD was found (all Pinteraction>0.05).ConclusionsNon-O blood groups are significantly associated with an increased risk of NAFLD. Our findings provide some epidemiological evidence for a possible role of ABO glycosyltransferase in the pathogenesis of NAFLD. However, these findings need to be validated by future studies.
In 2023, the most common blood type in South Korea was A-positive, with about 33.8 percent of the total blood donations. It was followed by O-positive and B-positive.
https://dataintelo.com/privacy-and-policyhttps://dataintelo.com/privacy-and-policy
The global ABO blood group reagent market size is projected to witness significant growth from $820 million in 2023 to approximately $1.4 billion by 2032, with a compound annual growth rate (CAGR) of 6.2%. The primary growth drivers of this market include the rising prevalence of chronic diseases, increased demand for blood transfusions, and advancements in diagnostic technologies. As healthcare systems worldwide continue to improve and expand, the need for accurate blood typing and cross-matching becomes critical, further driving the market's expansion.
One of the pivotal factors driving the growth of the ABO blood group reagent market is the increasing incidence of chronic diseases and trauma cases requiring blood transfusions. With the aging global population, conditions such as cancer, cardiovascular diseases, and orthopedic surgeries are becoming more prevalent, necessitating frequent blood transfusions. This increases the demand for reliable ABO blood group reagents, which are essential for ensuring patient safety during transfusions. Additionally, increased awareness about blood donation and the safety of blood transfusions is contributing to the market's growth.
Advancements in diagnostic technologies and automated blood typing systems are also propelling the ABO blood group reagent market forward. Modern diagnostic laboratories and blood banks are adopting automated systems that offer high precision and efficiency in blood typing and cross-matching. These advancements reduce human errors, enhance throughput, and improve the overall quality of diagnostic services. The integration of advanced technologies such as artificial intelligence and machine learning in blood group typing is further expected to open new avenues for market growth.
Government initiatives and regulations promoting safe blood transfusion practices are another critical factor contributing to market growth. Stringent guidelines and protocols established by health authorities such as the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA) ensure the implementation of reliable and accurate blood typing and cross-matching procedures. These regulations mandate the use of high-quality reagents, thus driving the demand for ABO blood group reagents.
The regional outlook of the ABO blood group reagent market highlights significant growth potential in various parts of the world. North America and Europe are anticipated to dominate the market due to advanced healthcare infrastructure, high healthcare expenditure, and the presence of key market players. Asia Pacific is expected to witness the highest growth rate, driven by an expanding healthcare sector, increasing awareness about blood donation, and supportive government policies. Latin America and the Middle East & Africa regions also present growth opportunities due to improving healthcare access and rising investment in healthcare infrastructure.
The ABO blood group reagent market is segmented by product type into Anti-A Reagents, Anti-B Reagents, Anti-AB Reagents, Anti-D Reagents, and Others. Anti-A reagents hold a prominent position in the market due to their critical role in determining the presence of A antigens in blood samples. These reagents are crucial for ensuring compatibility in blood transfusions and organ transplants. The increasing demand for accurate blood typing in hospitals and diagnostic laboratories is driving the growth of the Anti-A reagents segment.
Anti-B reagents are also witnessing substantial demand as they are essential for detecting B antigens in blood samples. Accurate determination of B antigens is vital for preventing adverse reactions during blood transfusions. The rising prevalence of conditions requiring blood transfusions, such as anemia and trauma, is contributing to the growth of the Anti-B reagents segment. Moreover, advancements in reagent formulations are enhancing the sensitivity and specificity of Anti-B reagents, further boosting their market adoption.
The Anti-AB reagents segment is gaining traction due to its importance in identifying AB blood group individuals. These reagents play a crucial role in blood typing, especially in emergency situations where rapid and accurate identification of blood groups is necessary. The increasing number of surgeries and medical procedures requiring
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 937.6(USD Billion) |
MARKET SIZE 2024 | 991.42(USD Billion) |
MARKET SIZE 2032 | 1550.0(USD Billion) |
SEGMENTS COVERED | Product Type, Technology, Application, End-User, Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Aging population technological advancements rising awareness increasing blood transfusions and favorable reimbursement policies |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | EKF Diagnostics, BioRad Laboratories, Inc., Agappe Diagnostics Ltd., Diagnostic Gene, HORIBA, Ltd., Hemocue AB, Human, Thermo Fisher Scientific, bioMerieux, Randox Laboratories Ltd., Allengers Medical, Ortho Clinical Diagnostics, Abbott Laboratories, FUJIFILM Wako Pure Chemical Corporation, Sysmex Corporation |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | Increasing demand for blood transfusions Technological advancements Growing focus on personalized medicine Rising awareness of bloodrelated disorders Expanding applications in genetics and research |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.74% (2025 - 2032) |
https://www.archivemarketresearch.com/privacy-policyhttps://www.archivemarketresearch.com/privacy-policy
The global blood group typing technology market is experiencing robust growth, driven by increasing demand for accurate and efficient blood transfusion procedures, rising prevalence of blood-related disorders, and the growing adoption of advanced diagnostic techniques. The market, estimated at $2.5 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033, reaching an estimated value of $4.2 billion by 2033. This expansion is fueled by several key factors. Technological advancements, such as the development of automated systems and point-of-care testing devices, are streamlining the blood typing process, improving accuracy, and reducing turnaround times. Furthermore, the increasing prevalence of chronic diseases requiring regular blood transfusions, coupled with a rising global population, significantly contributes to market growth. The shift towards personalized medicine and the need for precise blood type matching also contribute to market expansion. However, factors such as stringent regulatory requirements and the high cost associated with advanced technologies may pose challenges to market growth. The market is segmented based on technology (e.g., gel card technology, microplate technology, flow cytometry), product type (reagents, instruments, software), end-user (hospitals & blood banks, diagnostic laboratories), and geography. Key players such as Bio-Rad Laboratories, Merck Millipore, Ortho Clinical Diagnostics, and Danaher Corporation are driving innovation through continuous product development and strategic partnerships. The North American market currently holds a significant share, attributed to robust healthcare infrastructure and high adoption rates of advanced technologies. However, emerging markets in Asia-Pacific and Latin America are expected to witness significant growth in the coming years due to increasing healthcare expenditure and rising awareness about blood-related diseases. Overall, the blood group typing technology market is poised for continued expansion, driven by technological advancements, growing healthcare needs, and expanding global reach.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Demographic, clinical and laboratory characteristics of patients after multiple imputation.
This table contains 6720 series, with data for years 1994 - 1998 (not all combinations necessarily have data for all years). This table contains data described by the following dimensions (not all combinations are available): Geography (5 items: Territories; Yukon; Northwest Territories including Nunavut; Northwest Territories ...), Age group (14 items: Total; 12 years and over; 12-14 years; 15-19 years; 12-19 years ...), Sex (3 items: Both sexes; Females; Males ...), High blood pressure (4 items: Total population for the variable high blood pressure; Without high blood pressure; High blood pressure; not stated; With high blood pressure ...), Characteristics (8 items: Number of persons; Coefficient of variation for number of persons; Low 95% confidence interval - number of persons; High 95% confidence interval - number of persons ...).
https://www.marketreportanalytics.com/privacy-policyhttps://www.marketreportanalytics.com/privacy-policy
The global market for glass bead blood group test cards is experiencing robust growth, driven by several key factors. The increasing prevalence of blood transfusions, coupled with a rising global population and the consequent need for accurate and efficient blood typing, is a significant market driver. Furthermore, the convenience and cost-effectiveness of glass bead technology compared to traditional serological methods are contributing to its widespread adoption. Advancements in the technology, leading to improved accuracy, reduced testing time, and enhanced ease of use, further fuel market expansion. The rising incidence of blood-related diseases and the growing demand for reliable blood screening in developing economies are also creating substantial opportunities for market growth. While potential regulatory hurdles and the emergence of alternative technologies present some challenges, the overall market outlook remains positive. We project a steady CAGR (assuming a CAGR of 7% based on typical medical device market growth) over the forecast period, with a market size exceeding $500 million by 2033. Key players like Grifols, Bio-Rad, and Ortho Clinical Diagnostics are leading the innovation and market share, while regional variations reflect healthcare infrastructure and economic conditions. The market segmentation is diverse, with variations in demand based on product type (e.g., cards for specific blood group systems), end-user (hospitals, blood banks, diagnostic labs), and geographic region. North America and Europe currently dominate the market, driven by advanced healthcare infrastructure and high adoption rates. However, emerging markets in Asia-Pacific and Latin America are showing significant growth potential, indicating a shift towards broader global adoption. Competition among established players is intense, with companies focused on product differentiation through innovation in speed, accuracy, and ease of use. The future of the market is likely to see continued innovation, with a focus on automation, integration with existing laboratory information systems, and the development of point-of-care testing solutions to enhance accessibility and efficiency in diverse healthcare settings.
https://dataintelo.com/privacy-and-policyhttps://dataintelo.com/privacy-and-policy
The global blood group typing market size was valued at approximately USD 2.1 billion in 2023 and is projected to reach around USD 3.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.8% during the forecast period. This significant growth can be attributed to the increasing demand for safe blood transfusion, rising prevalence of chronic diseases, and advancements in technology related to blood group typing methodologies.
One of the primary growth factors of the blood group typing market is the rising incidence of chronic diseases and medical conditions that necessitate blood transfusion. Diseases such as cancer, hemophilia, and trauma cases require precise blood typing to ensure patient safety during transfusions. Furthermore, the growing number of surgical procedures, which often require blood transfusions, is another driving factor. The increasing adoption of blood group typing in prenatal screenings to prevent hemolytic disease in newborns is also contributing significantly to the market growth.
The advancements in technology are playing a crucial role in the blood group typing market. New methodologies such as polymerase chain reaction (PCR)-based techniques, microarray, and massively parallel sequencing have revolutionized the accuracy and efficiency of blood typing. These technological advancements reduce the risk of transfusion-related complications and improve patient outcomes. Moreover, the integration of artificial intelligence and machine learning in diagnostic processes is further enhancing the accuracy and speed of blood group typing, thereby fueling market growth.
Another critical factor contributing to the market growth is the increasing awareness and governmental initiatives promoting voluntary blood donation. Governments and NGOs are undertaking various programs to educate the public about the importance of blood donation and the need for safe transfusion practices. These initiatives are resulting in increased blood donation rates, which in turn is driving the demand for advanced blood group typing techniques. Additionally, the rising healthcare expenditure in developing countries is enabling the adoption of sophisticated blood typing technologies, further propelling market growth.
Regionally, North America is expected to hold the largest market share due to the high prevalence of chronic diseases, advanced healthcare infrastructure, and significant investment in research and development. Europe is also anticipated to witness substantial growth owing to the increasing number of blood donations and advancements in healthcare technology. The Asia Pacific region is projected to experience the highest growth rate, driven by the large population base, increasing awareness about blood donation, and improving healthcare facilities. Latin America and the Middle East & Africa are also poised for growth, albeit at a slower pace, due to ongoing development in healthcare infrastructure and rising awareness.
The product segment of the blood group typing market is categorized into instruments and reagents & kits. Instruments include automated and semi-automated analyzers used in blood typing, while reagents & kits encompass various antibodies, antigen kits, and other consumables necessary for blood typing procedures. The demand for instruments is driven by the need for high-throughput and accurate testing in hospitals and diagnostic laboratories. Automated analyzers are particularly gaining traction due to their ability to process large volumes of samples efficiently and with precision.
Reagents & kits hold a significant share in the market due to their recurring demand in routine blood typing tests. Continuous advancements and innovations in reagents, such as the development of monoclonal antibodies, are enhancing the accuracy and reliability of blood typing tests. The availability of a wide range of reagent kits designed for various blood typing techniques, including PCR-based and microarray methods, is further driving the market growth. Additionally, the increasing use of reagents in research laboratories for developing new blood typing methodologies is contributing to the segment's expansion.
The instruments segment is anticipated to witness considerable growth during the forecast period, driven by technological advancements and the rising adoption of automated systems in healthcare settings. The integration of advanced software and artificial intelligence in these instruments is further improving their efficiency and accura
CC0 1.0 Universal Public Domain Dedicationhttps://creativecommons.org/publicdomain/zero/1.0/
License information was derived automatically
Background: Different studies in worldwide showed conflicting results on association of Blood groups on SARS Cov-2 infection.
Objective: To observe the association of ABO blood groups on the presentation and outcomes of confirmed COVID -19 cases.
Design, Setting, and Participants: This was a Prospective cohort study of the patients with mild to moderately severe COVID -19 infections, presented in the COVID-19 unit of Dhaka Medical College Hospital. Participants were enrolled from 01 June to 25 august, 2020. Patient were followed up for at least 30 days after the onset of the disease. For the estimation we grouped A positive and A negative blood group into group-1 and other blood groups into group II.
Results: Total 438 patients were included in the cohort, 52 patients lost to follow up, 5 died and 381 patients completed the study. Prevalence of Blood group A [144(32.9 %)] was significantly higher among COVID-19 patients than the general population (p < 0.001).The Presenting age [{mean (SD)] of group I [42.1(14.5)] was higher than group II [38.8(12.4), p=0.014]. The gender (p=0.23) and co-morbidity (hypertension p=0.34, diabetes p=0.13) did not differ between the patients with group I and group II. Regarding Important Presenting symptoms, Fever (p=0.72), cough (p=0.69) and Respiratory distress (p=0.09), no difference were observed. There was no significant difference regarding the median duration of symptoms in group I 12(9-16)] days and group II [12 (8-15)], (HR, 95% CI,1.14 (0.91-1.41, p=0.25), conversion to next level of severity in group I 26 (20.6%) and in group II 36 (13.8%) (RR, 95%CI- 1.49 (0.94 - 2.35), p=0.09) and development of post COVD symptoms in group I 65 (51.6%) and in group II 107(41.1 %), (RR, 95%CI- 1.25 (1.00 - 1.57), p=0.05). But the persistent positivity of RT-PCR at 14 days of initial positivity in group I 24 (19%) and in group II (11.1 %) (RR, 95%CI-1.71 (1.04 - 2.81), p=0.04) was higher among the patients in group I.
Conclusions: Prevalence of blood group A was higher among COVID-19 patients. ABO blood group has no association with the presentation and recovery period of COVID-19. But patients with blood group-A had delayed sero conversion.
Open Government Licence - Canada 2.0https://open.canada.ca/en/open-government-licence-canada
License information was derived automatically
This table contains 401184 series, with data for years 2000 - 2000 (not all combinations necessarily have data for all years). This table contains data described by the following dimensions (Not all combinations are available): Geography (199 items: Canada; Newfoundland and Labrador; Health and Community Services Eastern Region; Newfoundland and Labrador (Peer group D);Health and Community Services St. John's Region; Newfoundland and Labrador (Peer group H) ...), Age group (14 items: Total; 12 years and over;12 to 19 years;15 to 19 years;12 to 14 years ...), Sex (3 items: Both sexes; Females; Males ...), Blood pressure check (6 items: Total; blood pressure check; Blood pressure check; within past 12 months; Blood pressure check; 2 or more years ago; Blood pressure check; 1 year to less than 2 years ago ...), Characteristics (8 items: Number of persons; Low 95% confidence interval; number of persons; Coefficient of variation for number of persons; High 95% confidence interval; number of persons ...).
The eight main blood types are A+, A-, B+, B-, O+, O-, AB+, and AB-. The most common blood type in the United States is O-positive, with around 38 percent of the population having this type of blood. However, blood type O-positive is more common in Latino-Americans than other ethnicities, with around 53 percent of Latino-Americans with this blood type, compared to 47 percent of African Americans and 37 percent of Caucasians. Blood donation The American Red Cross estimates that every two seconds someone in the United States needs blood or platelets, highlighting the importance of blood donation. It was estimated that in 2021, around 6.5 million people in the U.S. donated blood, with around 1.7 million of these people donating for the first time. Those with blood type O-negative are universal blood donors, meaning their blood can be transfused for any blood type. Therefore, this blood type is the most requested by hospitals. However, only about seven percent of the U.S. population has this blood type. Blood transfusion Blood transfusion is a routine procedure that involves adding donated blood to a patient’s body. There are many reasons why a patient may need a blood transfusion, including surgery, cancer treatment, severe injury, or chronic illness. In 2021, there were around 10.76 million blood transfusions in the United States. Most blood transfusions in the United States occur in an inpatient medicine setting, while critical care accounts for the second highest number of transfusions.